THC vs CBD

What is THC?

THC is a cannabinoid associated with cannabis intoxication and impairment.

Products may list THC alongside THCA and other cannabinoids. Read units and whether the number applies to a serving or full package. Higher THC does not automatically mean higher quality.

What is CBD?

CBD is a cannabinoid that does not produce the same intoxicating effect as THC, but it is not free of risk or regulatory limits.

FDA warns that CBD can cause side effects and interact with medications. Retail CBD claims should not be treated as medical advice or proof that a product is harmless.

Current stock, pricing, order requirements, and delivery estimates live in the official Nexus menu.

How should a THC-to-CBD ratio be read?

A ratio compares relative amounts, while the milligrams or percentage show concentration and total content.

Two 1:1 products can have very different amounts. Check package totals, serving statements, and product format rather than using the ratio alone.

Do THC and CBD predict how someone will feel?

No. Product form, timing, other constituents, personal biology, tolerance, and context can all matter.

Labels provide measured content, not a promise of mood, energy, sleep, relief, or performance. Avoid driving and other hazardous activity after cannabis use.

Can retail cannabis make medical claims about CBD?

Unapproved products should not be presented as diagnosing, treating, curing, or preventing disease.

FDA evaluates drugs through a formal approval process. A customer with a medical goal should speak with a qualified clinician and should not substitute a menu description for care.

What is the most reliable way to compare products?

Use the specific package's units, total amount, serving information, ingredients, batch record, and licensed source.

Ignore simplistic claims that one cannabinoid is universally good or bad. Preserve the label and use official recall and license tools when verification is needed.

How can a THC-to-CBD ratio be translated into actual content?

Read the labeled amount of each cannabinoid per serving or measure and for the entire package, because a ratio alone has no fixed strength.

A 1:1 product could contain one milligram of each cannabinoid in a serving or a much larger amount. Likewise, a 20:1 label can describe many total concentrations. Write the two milligram values beside the ratio, then note the number of declared servings and product form. Flower percentages, tincture milligrams per milliliter, and edible milligrams per serving should not be placed in one comparison column without their units.

Acidic cannabinoids can add another layer. A flower report may list THCA and THC separately and calculate total THC using a conversion formula. A package may also report CBDA and CBD. Use the label's definitions and the matched certificate rather than adding every number as if the forms were identical. Any large inconsistency should be referred to the manufacturer or retailer.

Keep the package units beside any ratio calculation so a later comparison does not mistake concentration, serving content, and full-package content for equivalent values.

Why is CBD not a universal low-risk category?

CBD can produce side effects, interact with medications, appear with THC, and be marketed in products whose claims or contents require careful verification.

FDA warns that CBD can affect how other drugs work and identifies concerns including liver injury, changes in alertness, gastrointestinal effects, and unresolved questions about long-term use. Those warnings make medical history relevant even when a product is not expected to produce THC's characteristic intoxication. A customer taking medication or managing a condition should bring the exact product information to a qualified healthcare professional.

The CBD label does not guarantee zero THC or a negative drug test. Check measured cannabinoids and remember that product and workplace testing have different thresholds and purposes. No retailer can promise an employment, probation, athletic, or roadside test result. Pregnancy and breastfeeding guidance also advises against assuming CBD is an acceptable substitute for THC-containing cannabis.

Which claims require more evidence than a cannabinoid label provides?

Promises to treat pain, anxiety, sleep disorders, inflammation, cancer, seizures, or another condition require clinical and regulatory support beyond retail cannabinoid content.

FDA has approved a specific prescription CBD medicine for particular seizure disorders. That approval does not transfer to every CBD gummy, tincture, flower, or topical. Product content and anecdotal reports do not establish that another formulation is equivalent in purity, amount, route, effectiveness, or medical supervision. Unapproved disease claims can delay appropriate diagnosis and care.

A responsible menu can describe cannabinoids, format, ingredients, batch results, and lawful product directions. It should not tell a customer to replace medication, skip a clinician, or expect a cure. When a marketing claim reaches beyond those boundaries, ask for the evidence and check an authoritative health source. The absence of THC-like intoxication is not proof of therapeutic effectiveness.